Generating AI analysis...
Revenue
$63.63B
++6.84% YoY
EPS (Basic)
$1.42
++273.68% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $63.63B | $59.55B | +6.84% |
Cost of Revenue | $17.85B | $24.95B | -28.46% |
Net Income | $8.03B | $2.12B | +279.00% |
EPS (Basic) | $1.42 | $0.38 | +273.68% |
EPS (Diluted) | $1.41 | $0.37 | +281.08% |
SG&A Expense | $14.73B | $14.77B | -0.28% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $213.4B | $226.5B | -5.79% |
Current Assets | $50.36B | $43.33B | +16.21% |
Total Liabilities | $124.9B | $137.21B | -8.97% |
Current Liabilities | $42.99B | $47.79B | -10.04% |
Stockholders' Equity | $88.2B | $89.01B | -0.91% |
Cash & Equivalents | $1.04B | $2.85B | -63.44% |
Long-Term Debt | $57.41B | $61.54B | -6.72% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $12.74B | $8.7B | +46.48% |
Investing Cash Flow | $2.65B | $-32.28B | +108.22% |
Financing Cash Flow | $-17.14B | $26.07B | -165.76% |
Share Buybacks | $0 | $0 | — |
D&A | $7.01B | $6.29B | +11.49% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 12.6% | — | — |
ROE | 9.1% | — | — |
ROA | 3.8% | — | — |
Current Ratio | $1.171 | — | — |
Debt to Equity | $1.416 | — | — |
Other companies in Pharmaceuticals